Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 6270-6275

  Chopra, Teena ^a   Marchaim, Dror ^a   Awali, Reda A ^a   Krishna, Amar ^a   Johnson, Paul ^a   Tansek, Ryan ^a   Chaudary, Khawar ^a   Lephart, Paul ^b   Slim, Jessica ^a   Hothi, Jatinder ^a   Ahmed, Harris ^a   Pogue, Jason M ^b   Zhao, Jing J ^b   Kaye, Keith S ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPHOTERICIN B; AZTREONAM; CARBAPENEM; CEFEPIME; COLISTIN; GENTAMICIN; IMIPENEM; LINEZOLID; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; SULTAMICILLIN; TIGECYCLINE; TOBRAMYCIN;

ACINETOBACTER INFECTION; ADULT; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL STRAIN; BLOOD CULTURE; BLOODSTREAM INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; DEMOGRAPHY; DRUG EXPOSURE; EXPOSURE; FEMALE; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; AGED, 80 AND OVER; AMPICILLIN; ANTI-BACTERIAL AGENTS; CARBAPENEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICHIGAN; MIDDLE AGED; RETROSPECTIVE STUDIES; SULBACTAM;

EID: 84887444173     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01520-13     Document Type: Article

References (29)

1. Furuno JP, Hebden JN, Standiford HC, Perencevich EN, Miller RR, Moore AC, Strauss SM, Harris AD. 2008. Prevalence of methicillinresistant Staphylococcus aureus and Acinetobacter baumannii in a longterm acute care facility. Am. J. Infect. Control 36:468-471.
2. Munoz-Price LS, Weinstein RA. 2008. Acinetobacter infection. N. Engl. J. Med. 358:1271-1281.
3. Pittet D, Dharan S. 2008. Alcohol-based rubs for hand antisepsis. Lancet Infect. Dis. 8:585-586.
4. Gilad J, Carmeli Y. 2008. Treatment options for multidrug-resistant Acinetobacter species. Drugs 68:165-189.
5. Paul M, Weinberger M, Siegman-Igra Y, Lazarovitch T, Ostfeld I, Boldur I, Samra Z, Shula H, Carmeli Y, Rubinovitch B, Pitlik S. 2005. Acinetobacter baumannii: emergence and spread in Israeli hospitals 1997-2002. J. Hosp. Infect. 60:256-260.
6. Centers for Disease Control and Prevention. 2004. Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004. MMWR Morb. Mortal. Wkly. Rep. 53:1063-1066.
7. Sengstock DM, Thyagarajan R, Apalara J, Mira A, Chopra T, Kaye KS. 2010. Multidrug-resistant Acinetobacter baumannii: an emerging pathogen among older adults in community hospitals and nursing homes. Clin. Infect. Dis. 50:1611-1616.
8. Abbo A, Navon-Venezia S, Hammer-Muntz O, Krichali T, Siegman-Igra Y, Carmeli Y. 2005. Multidrug-resistant Acinetobacter baumannii. Emerg. Infect. Dis. 11:22-29.
9. Brahmi N, Beji O, Abidi N, Kouraichi N, Blel Y, El Ghord H, Thabet H, Amamou M. 2007. Epidemiology and risk factors for colonization and infection by Acinetobacter baumannii in an ICU in Tunisia, where this pathogen is endemic. J. Infect. Chemother. 13:400-404.
10. Di Popolo A, Giannouli M, Triassi M, Brisse S, Zarrilli R. 2011. Molecular epidemiological investigation of multidrug-resistant Acinetobacter baumannii strains in four Mediterranean countries with a multilocus sequence typing scheme. Clin. Microbiol. Infect. 17:197-201.
11. Ho PL, Ho AY, Chow KH, Lai EL, Ching P, Seto WH. 2010. Epidemiology and clonality of multidrug-resistant Acinetobacter baumannii from a healthcare region in Hong Kong. J. Hosp. Infect. 74:358-364.
12. Wadl M, Heckenbach K, Noll I, Ziesing S, Pfister W, Beer J, Schubert S, Eckmanns T. 2010. Increasing occurrence of multidrug-resistance in Acinetobacter baumannii isolates from four German university hospitals, 2002-2006. Infection 38:47-51.
13. Keen EF, III, Murray CK, Robinson BJ, Hospenthal DR, Co EM, Aldous WK. 2010. Changes in the incidences of multidrug-resistant and extensively drug-resistant organisms isolated in a military medical center. Infect. Control Hosp. Epidemiol. 31:728-732.
14. Giske CG, Monnet DL, Cars O, Carmeli Y, ReAct-Action on Antibiotic Resistance. 2008. Clinical and economic impact of common multidrugresistant gram-negative bacilli. Antimicrob. Agents Chemother. 52:813-821.
15. Abbo A, Carmeli Y, Navon-Venezia S, Siegman-Igra Y, Schwaber MJ. 2007. Impact of multi-drug resistant Acinetobacter baumannii on clinical outcomes. Eur. J. Clin. Microbiol. Infect. Dis. 26:793-800.
16. Kuo LC, Lai CC, Liao CH, Hsu CK, Chang YL, Chang CY, Hsueh PR. 2007. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin. Microbiol. Infect. 13: 196-198.
17. Pankey GA. 2005. Tigecycline. J. Antimicrob. Chemother. 56:470-480.
18. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett JG, Edwards J, Jr, Infectious Diseases Society of America. 2008. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46:155-164.
19. Navon-Venezia S, Leavitt A, Carmeli Y. 2007. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 59:772-774.
20. Cisneros JM, Rodriguez-Bano J. 2002. Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin. Microbiol. Infect. 8:687-693.
21. Levin AS. 2003. Treatment of Acinetobacter spp infections. Expert Opin. Pharmacother. 4:1289-1296.
22. Tseng YC, Wang JT, Wu FL, Chen YC, Chie WC, Chang SC. 2007. Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii. Diagn. Microbiol. Infect. Dis. 59:181-190.
23. Reddy T, Chopra T, Marchaim D, Pogue JM, Alangaden G, Salimnia H, Boikov D, Navon-Venezia S, Akins R, Selman P, Dhar S, Kaye KS. 2010. Trends in antimicrobial resistance of Acinetobacter baumannii isolates from a metropolitan Detroit health system. Antimicrob. Agents Chemother. 54:2235-2238.
24. Munoz-Price LS, Zembower T, Penugonda S, Schreckenberger P, Lavin MA, Welbel S, Vais D, Baig M, Mohapatra S, Quinn JP, Weinstein RA. 2010. Clinical outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections: study of a 2-state monoclonal outbreak. Infect. Control Hosp. Epidemiol. 31:1057-1062.
25. Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, Kim M. 2009. Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infect. Control Hosp. Epidemiol. 30:1186-1192.
26. Levy SB, Marshall B. 2004. Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med. 10:S122-S129.
27. Lee NY, Lee HC, Ko NY, Chang CM, Shih HI, Wu CJ, Ko WC. 2007. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect. Control Hosp. Epidemiol. 28:713-719.
28. Jean SS, Hsueh PR, Lee WS, Chang HT, Chou MY, Chen IS, Wang JH, Lin CF, Shyr JM, Ko WC, Wu JJ, Liu YC, Huang WK, Teng LJ, Liu CY. 2009. Nationwide surveillance of antimicrobial resistance among non-fermentative Gram-negative bacteria in intensive care units in Taiwan: SMART programme data 2005. Int. J. Antimicrob. Agents 33:266-271.
29. Souli M, Galani I, Giamarellou H. 2008. Emergence of extensively drugresistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill. 13(47):pii:19045. http://www.eurosurveillance.org/ViewArticle.aspx? ArticleId=19045.